相关实验视频

Updated: May 17, 2025

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

塞夫特里亚克松会影响铁亡,并减轻帕金森病中的质细胞激活

Hui Zhi¹, Xiaoyu Wang², Yujia Chen¹

¹Department of Pharmacy, Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, Jiangsu 215153, P.R. China.

International journal of molecular medicine

|April 4, 2025

概括

塞夫特里亚克松 (CEF) 通过抑制细胞死亡途径铁亡来保护帕金森病 (PD). 在动物模型和细胞培养中观察到这种神经保护作用,这表明PD的治疗潜力.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
细胞生物学细胞生物学

背景情况:

帕金森病 (PD) 是一种流行的神经退行性疾病,其特征是多巴胺能神经元损失.
塞夫特里亚 (CEF) 在PD模型中表现有前途,但其神经保护机制尚不清楚.

研究的目的:

研究CEF在帕金森病中的神经保护机制.
在体内和体外探索CEF对多巴胺基神经元,微质细胞和天体细胞的影响.

主要方法:

使用了1-甲基-4--1,2,3,6-四甲 (MPTP) 和脂多糖 (LPS) 诱导的体内PD模型.
采用了体外模型,包括MPP+诱导的神经元损伤,LPS诱导的微质激活和TNFα诱导的天体细胞激活.
应用西斑,免疫光和qPCR测试来分析神经保护和分子通路.

主要成果:

在体内,CEF表现出神经保护作用,减少质细胞激活,恢复氨酸氧酶水平.
在体外,CEF直接保护神经元免受MPP+毒性和抑制质细胞激活.
机理学研究表明,CEF通过调节溶解物载体家族7成员11和谷氨过氧化酶4来抑制铁亡途径.

结论:

在帕金森病模型中,CEF表现出直接和间接的神经保护作用.
抑制铁亡是CEF神经保护作用的关键机制.
通过向铁亡,CEF对帕金森病具有重要的研究和治疗潜力.

关键词:

帕金森病是帕金森病的一种.星球细胞是星球细胞.塞夫特里亚克松是什么意思铁性化 (ferroptosis) 是一种谷氨过氧化酶4的作用微质细胞中的微质细胞神经炎症是一种神经炎症.溶解物载体家族 7 成员 11 成员 11

更多相关视频

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates

Published on: January 30, 2014

相关概念视频

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...